Literature DB >> 19914222

Drug-induced and genetic alterations in stress-responsive systems: Implications for specific addictive diseases.

Yan Zhou1, Dmitri Proudnikov, Vadim Yuferov, Mary Jeanne Kreek.   

Abstract

From the earliest work in our laboratory, we hypothesized, and with studies conducted in both clinical research and animal models, we have shown that drugs of abuse, administered or self-administered, on a chronic basis, profoundly alter stress-responsive systems. Alterations of expression of specific genes involved in stress responsivity, with increases or decreases in mRNA levels, receptor, and neuropeptide levels, and resultant changes in hormone levels, have been documented to occur after chronic intermittent exposure to heroin, morphine, other opiates, cocaine, other stimulants, and alcohol in animal models and in human molecular genetics. The best studied of the stress-responsive systems in humans and mammalian species in general is undoubtedly the HPA axis. In addition, there are stress-responsive systems in other parts in the brain itself, and some of these include components of the HPA axis, such as CRF and CRF receptors, along with POMC gene and gene products. Several other stress-responsive systems are known to influence the HPA axis, such as the vasopressin-vasopressin receptor system. Orexin-hypocretin, acting at its receptors, may effect changes which suggest that it should be properly categorized as a stress-responsive system. However, less is known about the interactions and connectivity of some of these different neuropeptide and receptor systems, and in particular, about the possible connectivity of fast-acting (e.g., glutamate and GABA) and slow-acting (including dopamine, serotonin, and norepinephrine) neurotransmitters with each of these stress-responsive components and the resultant impact, especially in the setting of chronic exposure to drugs of abuse. Several of these stress-responsive systems and components, primarily based on our laboratory-based and human molecular genetics research of addictive diseases, will be briefly discussed in this review. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19914222      PMCID: PMC2819563          DOI: 10.1016/j.brainres.2009.11.015

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  135 in total

1.  Mu opioid receptor knockdown in the substantia nigra/ventral tegmental area by synthetic small interfering RNA blocks the rewarding and locomotor effects of heroin.

Authors:  Y Zhang; M Landthaler; S D Schlussman; V Yuferov; A Ho; T Tuschl; M J Kreek
Journal:  Neuroscience       Date:  2008-10-02       Impact factor: 3.590

2.  Short-term hormonal effects of naloxone in man.

Authors:  J Volavka; J Bauman; J Pevnick; D Reker; B James; D Cho
Journal:  Psychoneuroendocrinology       Date:  1980       Impact factor: 4.905

Review 3.  Steroid hormones and the brain: cellular mechanisms underlying neural and behavioral plasticity.

Authors:  B S McEwen
Journal:  Psychoneuroendocrinology       Date:  1980-01       Impact factor: 4.905

4.  Thrombocytosis in the offspring of female mice receiving DL-methadone.

Authors:  Y Burstein; R W Grady; M J Kreek; A R Rausen; C M Peterson
Journal:  Proc Soc Exp Biol Med       Date:  1980-07

5.  Mechanisms of withdrawal-associated increases in heroin self-administration: pharmacologic modulation of heroin vs food choice in heroin-dependent rhesus monkeys.

Authors:  S Stevens Negus; Kenner C Rice
Journal:  Neuropsychopharmacology       Date:  2008-08-13       Impact factor: 7.853

6.  Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation.

Authors:  M J Kreek; R A Schaefer; E F Hahn; J Fishman
Journal:  Lancet       Date:  1983-02-05       Impact factor: 79.321

7.  Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine.

Authors:  Stephanie L Borgland; Sharif A Taha; Federica Sarti; Howard L Fields; Antonello Bonci
Journal:  Neuron       Date:  2006-02-16       Impact factor: 17.173

8.  Effect of chronic naltrexone and methadone administration on brain immunoreactive beta-endorphin in the rat.

Authors:  V V Ragavan; S L Wardlaw; M J Kreek; A G Frantz
Journal:  Neuroendocrinology       Date:  1983-10       Impact factor: 4.914

9.  Methadone disposition during the perinatal period in humans.

Authors:  M J Kreek
Journal:  Pharmacol Biochem Behav       Date:  1979       Impact factor: 3.533

10.  Distinct melanocortin 2 receptor accessory protein domains are required for melanocortin 2 receptor interaction and promotion of receptor trafficking.

Authors:  Tom R Webb; Li Chan; Sadani N Cooray; Michael E Cheetham; J Paul Chapple; Adrian J L Clark
Journal:  Endocrinology       Date:  2008-09-25       Impact factor: 4.736

View more
  24 in total

1.  Hypocretin receptor 2 antagonism dose-dependently reduces escalated heroin self-administration in rats.

Authors:  Brooke E Schmeichel; Estelle Barbier; Kaushik K Misra; Candice Contet; Joel E Schlosburg; Dimitri Grigoriadis; John P Williams; Camilla Karlsson; Caleb Pitcairn; Markus Heilig; George F Koob; Leandro F Vendruscolo
Journal:  Neuropsychopharmacology       Date:  2015-03-13       Impact factor: 7.853

Review 2.  Extreme marginalization: addiction and other mental health disorders, stigma, and imprisonment.

Authors:  Mary Jeanne Kreek
Journal:  Ann N Y Acad Sci       Date:  2011-08       Impact factor: 5.691

Review 3.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

4.  Treatment-like steady-state methadone in rats interferes with incubation of cocaine sensitization and associated alterations in gene expression.

Authors:  Francesco Leri; Yan Zhou; Brendan Carmichael; Erin Cummins; Mary Jeanne Kreek
Journal:  Eur Neuropsychopharmacol       Date:  2011-07-13       Impact factor: 4.600

5.  Association of polymorphisms of the mu opioid receptor gene with the severity of HIV infection and response to HIV treatment.

Authors:  Dmitri Proudnikov; Matthew Randesi; Orna Levran; Howard Crystal; Magdalena Dorn; Jurg Ott; Ann Ho; Mary Jeanne Kreek
Journal:  J Infect Dis       Date:  2012-03-28       Impact factor: 5.226

6.  Persistent increases in rat hypothalamic POMC gene expression following chronic withdrawal from chronic "binge" pattern escalating-dose, but not steady-dose, cocaine.

Authors:  Y Zhou; M J Kreek
Journal:  Neuroscience       Date:  2015-01-13       Impact factor: 3.590

7.  Mu-opioid receptor A118G polymorphism in healthy volunteers affects hypothalamic-pituitary-adrenal axis adrenocorticotropic hormone stress response to metyrapone.

Authors:  Elizabeth Ducat; Brenda Ray; Gavin Bart; Yoshie Umemura; Jack Varon; Ann Ho; Mary Jeanne Kreek
Journal:  Addict Biol       Date:  2011-04-20       Impact factor: 4.280

8.  Evidence that vasopressin V1b receptors mediate the transition to excessive drinking in ethanol-dependent rats.

Authors:  Scott Edwards; Miguel Guerrero; Ola M Ghoneim; Edward Roberts; George F Koob
Journal:  Addict Biol       Date:  2011-02-11       Impact factor: 4.280

9.  Cocaine place conditioning increases pro-opiomelanocortin gene expression in rat hypothalamus.

Authors:  Y Zhou; A Kruyer; A Ho; M J Kreek
Journal:  Neurosci Lett       Date:  2012-10-13       Impact factor: 3.046

10.  Suppression of hypothalamic-pituitary-adrenal axis by acute heroin challenge in rats during acute and chronic withdrawal from chronic heroin administration.

Authors:  Yan Zhou; Francesco Leri; Ann Ho; Mary Jeanne Kreek
Journal:  Neurochem Res       Date:  2013-06-16       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.